Niko Nikolaou, M.D. – Clinical Pathology & Complex Disease Management

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
    • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
    • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.

  </ul class=”cutome-font”>

• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

• *Lumbar puncture for severe older patients
• If/as applicable, scaffolding optional but not necessary.
• Applications spread over consecutive months unless otherwise specified by clinician.
• Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
  • Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  • Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  • Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
• Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
• Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
• Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
• Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.